| HOME >> MEDICINE >> TECHNOLOGY |
CONTACTS:For Media Inquiries: For Investor Inquiries:Jared Tipton
Jacquie RossCepheid Corporate Communications
Cepheid Investor RelationsTel: (408) 400 8377
Tel: (408) 400 8329communications@cepheid.com
investor.relations@cepheid.com FINANCIAL TABLES FOLLOWCEPHEID
CONDENSED CONSOLIDATED UNAUDITED STATEMENTS OF OPERATIONS(in thousands, except per share data)
Three Months Ended
March 31,20122011Revenues:System sales
$
3,231$
2,691Reagent and disposable sales
62,06244,946Total product sales
75,29357,637Other revenues
1,9992,582Total revenues
77,29260,219Costs and operating expenses:Cost of product sales
35,60825,310Collaboration profit sharing
1,6841,092Research and development
22,10213,574Sales and marketing
14,51211,447General and administrative
11,0517,630Total costs and operating expenses
84,95759,053Income (loss) from operations
(7,665)1,166Other income (expense), net
238(199)Income (loss) before income taxes
(7,427)967Benefit from (provision for) income taxes
1,901(440)Net income (loss)
$
(5,526)$
527Basic net income (loss) per share
$
(0.08)$
.01Diluted net income (loss) per share
$
(0.08)$
.01Shares used in computing basic net income (loss) per share
65,02761,161Shares used in computing diluted net income (loss) per share
65,02765,028
| SOURCE Cepheid Copyright©2010 PR Newswire. All rights reserved |